

SUPPORTING INFORMATION

***α*-Glucosidase inhibitory tetraoxygenated xanthenes from the twig extract of *Garcinia cowa* Roxb. ex Choisy**

Nguyen Thi Kim An¹,⁰⁰⁰⁰⁻⁰⁰⁰²⁻²⁵⁹²⁻⁴⁹⁵⁰, Nguyen Thanh Tra²,⁰⁰⁰⁰⁻⁰⁰⁰³⁻³³⁵¹⁻¹²⁰⁵, Doan Lan Phuong²,⁰⁰⁰⁰⁻⁰⁰⁰³⁻²⁵¹⁴⁻⁹⁸²⁴, Pham Thi Tham¹,^{0000-0001-5070-686X}, Tran Thi Thu Thuy^{2*},⁰⁰⁰⁰⁻⁰⁰⁰²⁻⁶⁷⁷⁰⁻³²⁹¹

¹ Hanoi University of Industry, 298 Cau Dien, Hanoi 122100, Vietnam.

²Institute of Chemistry, Vietnam Academy of Science and Technology, 18 Hoang Quoc Viet, Nghia Do, Hanoi 122100, Vietnam.

* Corresponding author: Tran Thi Thu Thuy (thuy.tran@ich.vast.vn)

Abstract

Phytochemical investigation of the twigs of *Garcinia cowa* Roxb. ex Choisy (Clusiaceae), collected in Vietnam, led to the isolation of five tetraoxygenated xanthenes, including three new compounds, namely norrubraxanthone (**1**), garcinone G (**2**), and garcinone H (**3**), together with two known compounds, *α*-mangostin (**4**) and rubraxanthone (**5**). The structures of the new compounds were elucidated by comprehensive spectroscopic analyses, including 1D and 2D NMR and high-resolution electrospray ionization mass spectrometry (HR-ESI-MS), and by comparison with literature data. All isolated compounds were evaluated for their *in vitro* *α*-glucosidase inhibitory activity. Compounds **1–5** exhibited potent inhibitory effects, with IC₅₀ values ranging from 0.39 to 1.62 μM, which were significantly stronger than that of the positive control acarbose (IC₅₀ = 263.01 ± 10.92 μM). Among them, compounds **3** and **4** showed the most pronounced activity, with IC₅₀ values of 0.43 ± 0.01 and 0.39 ± 0.01 μM, respectively.

Keywords: Tetraoxygenated xanthone, *Garcinia cowa*, *α*-glucosidase, antidiabetic.

LIST OF FIGURES AND TABLE

1. Figure S1. (+)ESI-HR-MS spectrum of compound **1**
2. Figure S2. ^1H NMR spectrum (in CD_3OD) of compound **1**
3. Figure S3. ^{13}C NMR spectrum (in CD_3OD) of compound **1**
4. Figure S4. HSQC spectrum of compound **1**
5. Figure S5. HMBC spectrum of compound **1**
6. Figure S6. UV spectra of compound **1**
7. Figure S7. (+)ESI-HR-MS spectrum of compound **2**
8. Figure S8. ^1H NMR spectrum (in CD_3OD) of compound **2**
9. Figure S9. ^{13}C NMR spectrum (in CD_3OD) of compound **2**
10. Figure S10. HSQC spectrum of compound **2**
11. Figure S11. HMBC spectrum of compound **2**
12. Figure S12. UV spectra of compound **2**
13. Figure S13. (+)ESI-HR-MS spectrum of compound **3**
14. Figure S14. ^1H NMR spectrum (in CD_3OD) of compound **3**
15. Figure S15. ^{13}C NMR spectrum (in CD_3OD) of compound **3**
16. Figure S16. HMBC spectrum of compound **3**
17. Figure S17. UV spectra of compound **3**
18. Figure S18. ^1H NMR spectrum (in CD_3OD) of compound **4**
19. Figure S19. ^{13}C NMR spectrum (in CD_3OD) of compound **4**
20. Figure S20. ^1H NMR spectrum (in CD_3OD) of compound **5**
21. Figure S21. ^{13}C NMR spectrum (in CD_3OD) of compound **5**
22. Table S1. α -Glucosidase inhibition effect of compounds **1-5**




Figure S1. (+)ESI-HR-MS spectrum of compound 1.




Figure S2. ¹H NMR spectrum (in CD₃OD) of compound 1.




Figure S3. ^{13}C NMR spectrum (in CD_3OD) of compound **1**.




Figure S4. HSQC spectrum of compound 1.




Figure S5. HMBC spectrum of compound 1.




Figure S6. UV spectra of compound 1.




Figure S7. (+)ESI-HR-MS spectrum of compound 2.




Figure S8. ^1H NMR spectrum (in CD_3OD) of compound **2**.




Figure S9. ^{13}C NMR spectrum (in CD_3OD) of compound **2**.




Figure S10. HSQC spectrum of compound 2.




Figure S11. HMBC spectrum of compound 2.




Figure S12. UV spectra of compound 2.




Figure S13. (+)ESI-HR-MS spectrum of compound 3.




Figure S14. ^1H NMR spectrum (in CD_3OD) of compound **3**.




Figure S15. ^{13}C NMR spectrum (in CD_3OD) of compound **3**.




Figure S16. HMBC spectrum of compound 3.




Figure S17. UV spectra of compound 3.




Figure S18. ^1H NMR spectrum (in CD_3OD) of compound 4.




Figure S19. ^{13}C NMR spectrum (in CD_3OD) of compound 4.




Figure S20. ^1H NMR spectrum (in CD_3OD) of compound 5.




Figure S21. ^{13}C NMR spectrum (in CD_3OD) of compound **5**.

Table S1. α -Glucosidase inhibition effect of compounds 1-5

No	Compound	Concentration ($\mu\text{g/ml}$)	Inhibition (%)	IC ₅₀ (μM)
1	1	16	86.5	1.62 \pm 0.05
		4	74	
		1	67	
		0,25	32	
		0,06	11	
2	2	16	96	0.94 \pm 0.14
		4	90.5	
		1	87	
		0,25	40.5	
		0,06	13	
3	3	16	98	0.43 \pm 0.01
		4	95	
		1	93.5	
		0,25	67,5	
		0,06	11,5	
4	4	16	95	0.39 \pm 0.01
		4	93	
		1	81	
		0,25	76.5	
		0,06	19	
5	5	16	95	0.56 \pm 0.03
		4	83	
		1	75	
		0,25	53.5	
		0,06	8	
6	Acarbose	256	72	263.01 \pm 10.92
		64	23	
		16	18	
		4	5	
		1	0	